(Reuters) -India’s GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio.

The Indian unit of British drugmaker GSK reported consolidated profit of 2.57 billion rupees ($29 million) in the quarter ended September 30, up 2% from last year.

Its revenue from operations decreased 3% to 9.8 billion rupees, down for a second quarter in a row.

KEY CONTEXT

GlaxoSmithKline Pharma, an industry leader in pediatric vaccines, is making inroads into the adult vaccine market with its shingles vaccine Shingrix, which has boosted earnings.

Supply constraints and the transitory impact of GST changes impacted pharma sales in the quarter, the company highlighted.

While the company’s key brands such as antibiot

See Full Page